Study on Olverembatinib for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Inclusion Criteria

• Newly diagnosed with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
• Expected to live for at least 3 more months.
• In relatively good health with an ECOG performance status of 2 or lower, meaning fully active or able to carry out light work.
• Have adequate organ function as determined by medical tests.

Exclusion Criteria

• Have a history of chronic myeloid leukemia (CML).
• Have signs of leukemia affecting the brain or other areas outside the bone marrow, except for enlarged lymph nodes or liver/spleen.
• Have current or past diseases affecting the brain or nervous system.
• Have autoimmune diseases that might affect the brain.
• Are taking high doses of blood thinners or medications that affect blood clotting; low doses are allowed.
• Are using medications that interact with the study drug within a week before starting the study.
• Have uncontrolled heart diseases.
• Have had blood clots in the veins or lungs in the past 6 months.
• Are using medications that are not allowed in the study.
• Have unstable medical conditions that might affect safety or participation in the study.
• Are taking medications that can cause heart rhythm problems.
• Have active infections needing treatment.
• Have conditions affecting the ability to take or absorb oral medications, or have active stomach ulcers.
• Cannot use glucocorticoids due to medical reasons.
• Have bleeding disorders not related to leukemia.
• Plan to have major surgery.
• Are allergic to ingredients in the study drugs.
• Are pregnant, breastfeeding, or planning to become pregnant during the study.
• Have had other cancers within the past 2 years.
• Have any symptoms or conditions that might interfere with the study or are not suitable for participation.